Biocon Biologics Bolstered By Goldman Sachs Investment

Deal Worth $150m Values Biocon Subsidiary At Nearly $4bn

 
• By David Wallace
  
Goldman Sachs
Goldman Sachs is investing in Biocon Biologics • Source: Shutterstock

More from Deals

More from Business